The study objective was to determine which antibiotics are optimal in the treatment of children with complicated acute bronchitis with bronchospasm. For that, a Monte-Carlo simulation was conducted.
Introduction
Acute obstructive bronchitis is frequent in children. The repeated (2-3 times or more within one year) episodes of bronchitis with bronchospasm are a recurrent type of obstructive bronchitis. The pathogenesis of recurrent obstructive bronchitis is complex. Infectious factors are of the paramount importance. Bacterially induced inflammation develops through acute respiratory viral infection (ARVI). The bacterial overgrowth contributes to further inflammation, both by damage to the bronchial structure itself and by activation of enzymes in inflammatory cells, resulting in mucociliary clearance impairment. This, in turn, promotes the development of pan-bronchitis and peri-bronchitis and contributes to the development of deforming bronchitis. The antibiotic therapy plays a significant role, not only resolving the symptoms of acute inflammation, but also eradicating the pathogen, eventually decreasing the number of repeated bouts, the inter-exacerbation interval, thus, improving the patients' quality of life. The starter drug is selected empirically, considering the probable etiology and sensitivity of the presumed pathogen to antimicrobials.
One of the major directions when planning and defining the priority therapeutic measures is a clinical and economic analysis of a drug therapy. Using the results of this clinical and financial evaluation can optimize a drug prescription system, prevent the prescription of unnecessary drugs, and also determine the most effective medicines for a specific nosology. Comparative assessment of the quality of two and more methods of prevention, diagnostics, medical and non-medical treatment is the primary method of the clinical and economic analysis.
While an experiment on the real object is often impossible, pharmacoeconomics frequently uses simulation, in particular, Monte-Carlo method (Barton et al. 2004 ). Monte-Carlo simulation was also used to evaluate the incidence at the population level (Stuebe et al. 2017) , to compare the costs and efficiency of empirical treatment including ceftolozane/tazobactam or piperacillin/tazobactam in gram-negative hospitalized patients (Kauf et al. 2017) . Monte-Carlo simulation is a common name for a group of numerical methods based on obtaining a large number of representations of stochastic (random) process, which is formed in such a way that its probabilistic characteristics match the similar values of the task at hand.
The Monte-Carlo method reproduces and studies the behavior of all the components of the system under study (Briggs et al. 2007 ).
The study was aimed to determine the clinically and economically optimal antibiotics for the treatment of acute bronchitis complicated with bronchospasm in children using Monte-Carlo simulation.
Materials and methods
The analysis included retrospective evaluation of 2 519 physicians' prescriptions from the case histories from 2008 to 2014 in three medical centers of Nizhny Novgorod (Russian Federation). The patients were from 0 to 18 years old. To 31.0% (n=781) of the patients, no antibiotics were prescribed. Also, the study excluded case histories of the patients in whom the antibiotic therapy had caused side effects in the form of allergic reactions (5.3%, n=134). No cases of dysbiosis were noted, as the antibiotic therapy was administered along with probiotics. The study population included only the case histories from 1604 patients who had been receiving the antibiotic therapy.
In this study, the number of boys with acute bronchitis with bronchospasm exceeded the number of girls by 1.5 times. The narrower airways, an increased tonus of smooth muscles of the bronchial tree and a higher level of IgE (immunoglobulin E) explain an increased risk of developing acute bronchitis with bronchospasm in boys relative to girls.
The highest number of cases of complicated bronchitis with bronchospasm was observed in children under six years old. The patient distribution by age was: 1) 0-1 y/o -663 (41.3%); 2) 1-3 y/o -550 (34.3%); 3) 3-6 y/o -312 (19.5%); 4) > 6 y/o -79 (4.93%). That predominance can be explained by an immature immune system of the children, and by their susceptibility to colds often complicated by bronchitis (which can further lead to bronchial obstruction).
The start drug was chosen empirically, considering the probable etiology and sensitivity of the presumed pathogen to antimicrobials (Table 1 ). The antibiotics in acute bronchitis in children were prescribed for the following reasons: severe intoxication, fever lasting more than three days, the presence of an obstructive syndrome, clinical signs of bronchitis, an early age of the patient, and a (2013), and 31.2% (2014) of the cases. The number of children with recurrent bronchial obstruction was 40.7%. Currently, the most common antibacterials to treat bronchitis were three groups of antibiotics, so-called "gold standard drugs": penicillins (amoxicillin, inhibitor-protected penicillins), II-III generation cephalosporins, and macrolides. The cost of an antibiotic treatment course was calculated by multiplying the average dosage of the drug (mg) by administration frequency, by the average treatment duration (days), and by the price of 1 mg of the antibiotic (US$).
The average duration of cephalosporines therapy was 8.5 (8.51±1.41) days, of inhibitor-protected penicillin (amoxicillin/clavulanate) -7 days, and of macrolides, it varied from 3-5 days for azithromycin to 10 days for midecamycin. With ineffective antibiotic treatment, the treatment duration could be increased to 10-13.5 days. In this case, after a course of antibiotic therapy, the disease symptoms persisted in 35.7% of the cases. In 37.1% of these patients, another course of antibacterial drugs of a different class (sequential antibiotic therapy) was prescribed. The following changes were made: cephalosporin/macrolide (76.5%), inhibitor-protected penicillin/macrolide (15.0%), and cephalosporin/inhibitor-protected penicillin (8%). The sequential antibiotic therapy conduced to the favorable clinical outcomes in 100% of the cases.
The efficiency of an antibiotic therapy was evaluated by the rate of positive clinical outcomes, using the initially prescribed drug without adding any other ethiotropic drugs. Positive clinical outcomes, such as "recovery" or "significant improvement", were registered by a physician in each case history. The clinical outcome was considered positive in cases of body temperature normalization, elimination of intoxication, elimination of bronchial obstruction, and normalization of humoral activity.
When using Monte-Carlo method for the cost-effectiveness analysis, a mathematical model was created for each treatment method to evaluate. Using this model, the cost-effectiveness ratio was calculated for each of the treatment methods under comparison. This analysis was performed in three stages:
• constructing a mathematical relationship between the data sought for and the variable parameters, such as the cost of medical resources, the probability of the clinical outcome, etc.; • estimating types of mathematical distributions to describe the distribution of particular variable parameters: • Monte-Carlo simulation itself.
The input data for the model included the costs of an antibiotics therapy, as well as the probabilities of clinical outcomes for different methods of treatment. There were two possible clinical outcomes of the antibiotics therapy: 1) positive clinical effect (recovery), or 2) adverse clinical effect. It was assumed that all the experimental data were as a set of random numbers that are subject to certain statistical distributions. To calculate the probability of a clinical outcome, beta-distribution was used, and to describe costs, a gamma-distribution was used. Beta-distribution is typically used when describing probabilities for the binomial data (ill or healthy). In the probability theory and statistics, beta-distribution is used as a two-parameter family of absolutely continuous distributions. It is limited to the interval from 0 to 1 and is characterized by two parameters, α and β. Parameters of beta-distribution are calculated on the basis of the existing experimental data. Considering the sample of n events (the patients who used the drug studied), and taking the number of successful uses as r (the number of positive clinical outcomes when using the examined antibiotic), then the parameters α and β are defined as α = r, β= n -r. Thus, beta-distribution fits the objectives of the study.
As noted above, the costs are usually described by using gamma-distribution. In the probability theory, it is considered as a two-parameter family of absolutely continuous distributions.
This choice was based on the assumption that the gamma-distribution is defined and is continuous in the range from 0 to infinity, which is more appropriate to describe costs.
Based on beta-and gamma-distributions with the parameters set for each antibiotic, samples were generated, containing 1000 random uses each. Then the cost-effectiveness ratio was calculated in each sample.
Results and discussion
In the analyzed period, two groups of antibiotics: β-lactams (cephalosporins, protected penicillins), and macrolides were used for treatment of acute bronchitis with bronchospasm. The injections of cephalosporins were prescribed most often (57.8%).
From the cephalosporins, cefotaxime (56.9%), ceftriaxone (23.0%), cefuroxime (13.8%), and cefazolin (6.3%) were mostly used. Cefazolin was excluded from the further analysis due to the low frequency of its presciprion (to fewer than 100 patients) and, therefore, the impossibility to evaluate its clinical and economic component.
Of the protected penicillins group, the only drug used was amoxicillin/clavulanic (16.3%). Macrolides were prescribed in 25.9% of the cases. Of the macrolides, azithromycin (65.6%), clarithromycin (9.5%), spiramycin (18.9%), and midecamycin (6%) were mainly used.
The antimicrobial therapy of acute bronchitis with bronchospasm was most efficient ("recovery") when using macrolides. The clinical outcomes "significant improvement" and "recovery" after using cephalosporins and protected penicillins were observed when there were co-morbidities, such as otitis, sinusitis, and tonsillitis, which are often accompanied by fever and intoxication.
Low efficiency of cephalosporins and protected penicillins in the treatment of acute bronchitis with bronchospasm without any co-morbidities can indicate an allergic, atypical bacterial, or viral nature of acute bronchitis with bronchospasm (Table 2) .
During the study, the models for β-lactam antibiotics (protected penicillins and cephalosporins) were constructed ( Fig. 1) . Figure 1 shows that the cefuroxime course is the most expensive. The least expensive is the course of amoxicillin/clavulanic acid. The most effective are the courses of cefotaxime, with the probability of a positive clinical outcome when using this drug being much higher in comparison with the other drugs.
To compare the clinical efficacy of β-lactam antibiotics, the curves of beta-distributions of the effectiveness of the studies antibiotics were constructed (Fig. 2) .
If the curve is narrow and sharply peaked, the measurement results (in this case, the probability of a positive clinical outcome) are highly reproducible. When the curve is broad and shallow, the reproducibility of the drug effect is low. The simulation showed that clinically and economically, the most efficient of the β-lactam antibiotics is cefotaxime, despite the fact that its CER=7.78, which is 2.65 times higher than that for amoxicillin/clavulanic acid (CER=2.93).
During the next phase of the study, the clinical and economic effectiveness of the macrolides widely used in the treatment of acute bronchitis with bronchospasm in the hospitalized children was simulated.
The models of costs and efficacy distribution were constructed for macrolides (Fig. 3) .
The azithromycin groups have the greatest clinical efficacy (Fig. 3) . Midecamycin has the lowest CER among macrolides, with a wide scatter of possible clinical efficacy. The most expensive of macrolides is a clarithromycin course. At the same time, it has a wider scatter of distribution points. Azithromycin groups have the highest clinical efficacy, with the narrowest scatter of distribution points.
To compare the clinical efficacy, the curves of beta-distribution of the effectiveness of the antibiotics analyzed were plotted (Fig. 4) .
The azithromycin beta-distribution curve is narrow, sharply peaked and shifted to the right, indicating the high clinical efficacy of the antibiotic for the treatment of the disease studied, which proves the feasibility of using azithromycin. However, the values obtained through the simulation can vary with different samples of patients. Therefore, at the next stage of the study, it was identified how significant those changes were, and what were the minimum ranges covering the exact actual value of the desired frequencies, i.e., a minimum interval that contained the real value of the sought for clinical efficacy with a probability of 95%, which is known in statistics as the 95% confidence interval (95%CI). In practice, the 95% confidence interval means that 95% of the potential samples of the drug use for the studied disease will provide the values of clinical efficacy that fall within the resulting intervals, with only 5% of values lying outside. For this purpose, the area under the curve of beta-distribution of clinical outcomes for β-lactam antibiotics used in the treatment of acute bronchitis with bronchospasm in children was found, with 2.5% of the area being cut on the right and on the left. The corresponding x values were considered the minimum (min (95%)) and the maximum (max (95%)) confidential clinical efficacy (Table 3 ).
The Table shows that cefotaxime is the best β-lactam, with the 95% confidence interval of clinical efficacy from 0.585 to 0.655.
The most optimal of macrolides are azithromycines (0.947-0.982), providing the smallest interval of probable clinical efficacy for the disease studied. Figure 4 . Beta-distribution of outcomes for the macrolides antibiotics, used in the treatment of acute bronchitis with bronchospasm in children.
